Literature DB >> 23510726

Anti-cytokine therapies in T1D: Concepts and strategies.

Gerald T Nepom1, Mario Ehlers, Thomas Mandrup-Poulsen.   

Abstract

Therapeutic targeting of proinflammatory cytokines is clinically beneficial in several autoimmune disorders. Several of these cytokines are directly implicated in the pathogenesis of type 1 diabetes, suggesting opportunities for design of clinical trials in type 1 diabetes that incorporate selective cytokine blockade as a component of preventative or interventional immunotherapy. The rationale and status of inhibitory therapy directed against IL-1, TNF, IL-12, IL-23, and IL-6 are discussed, towards a goal of using cytokine inhibition as a therapeutic platform to establish an in vivo milieu suitable for modulating the immune response in T1D.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-inflammatory; Autoimmunity; DAMPs; IL-1 receptor accessory protein; IL-1 receptor antagonist; IL-1RA; IL-1RAcP; Immunotherapy; LPS; NOD; ROS; Regulatory T cells; T1D; T2D; TLR; TXNIP; Teff; Treg; damage/danger-associated molecular patterns; effector T cell(s); lipopolysaccharide; non-obese diabetic (mice); reactive oxygen species; regulatory T cell(s); thioredoxin inhibitory protein; toll-like receptor; type 1 diabetes; type 2 diabetes

Mesh：

Substances：

Year:  2013        PMID： 23510726      PMCID： PMC3700624          DOI： 10.1016/j.clim.2013.02.003

Source DB:  PubMed          Journal:  Clin Immunol        ISSN： 1521-6616            Impact factor:   3.969


  59 in total

1.  Suppression of cyclophosphamide induced diabetes development and pancreatic Th1 reactivity in NOD mice treated with the interleukin (IL)-12 antagonist IL-12(p40)2.

Authors:  H Rothe; R M O'Hara; S Martin; H Kolb
Journal:  Diabetologia       Date:  1997-06       Impact factor: 10.122

2.  Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes.

Authors:  S Trembleau; G Penna; S Gregori; M K Gately; L Adorini
Journal:  Eur J Immunol       Date:  1997-09       Impact factor: 5.532

Review 3.  The role of interleukin-1 in the pathogenesis of IDDM.

Authors:  T Mandrup-Poulsen
Journal:  Diabetologia       Date:  1996-09       Impact factor: 10.122

4.  Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity.

Authors:  T Mandrup-Poulsen; K Bendtzen; C A Dinarello; J Nerup
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

5.  Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice.

Authors:  K Fujihira; M Nagata; H Moriyama; H Yasuda; K Arisawa; M Nakayama; S Maeda; M Kasuga; K Okumura; H Yagita; K Yokono
Journal:  Diabetes       Date:  2000-12       Impact factor: 9.461

6.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

Authors:  William J Sandborn; Christopher Gasink; Long-Long Gao; Marion A Blank; Jewel Johanns; Cynthia Guzzo; Bruce E Sands; Stephen B Hanauer; Stephan Targan; Paul Rutgeerts; Subrata Ghosh; Willem J S de Villiers; Remo Panaccione; Gordon Greenberg; Stefan Schreiber; Simon Lichtiger; Brian G Feagan
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

7.  IL-12 administration accelerates autoimmune diabetes in both wild-type and IFN-gamma-deficient nonobese diabetic mice, revealing pathogenic and protective effects of IL-12-induced IFN-gamma.

Authors:  Sylvie Trembleau; Giuseppe Penna; Silvia Gregori; Nadia Giarratana; Luciano Adorini
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

8.  Prevention of recurrent but not spontaneous autoimmune diabetes by transplanted NOD islets adenovirally transduced with immunomodulating molecules.

Authors:  Muneaki Sakata; Hisafumi Yasuda; Hiroaki Moriyama; Katsumi Yamada; Reiko Kotani; Midori Kurohara; Yasuyo Okumachi; Minoru Kishi; Takashi Arai; Kenta Hara; Hirofumi Hamada; Koichi Yokono; Masao Nagata
Journal:  Diabetes Res Clin Pract       Date:  2008-04-08       Impact factor: 5.602

9.  Local expression of immunoregulatory IL-12p40 gene prolonged syngeneic islet graft survival in diabetic NOD mice.

Authors:  H Yasuda; M Nagata; K Arisawa; R Yoshida; K Fujihira; N Okamoto; H Moriyama; M Miki; I Saito; H Hamada; K Yokono; M Kasuga
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

10.  Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice.

Authors:  S Trembleau; G Penna; E Bosi; A Mortara; M K Gately; L Adorini
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307
View more
  28 in total

1.  Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease.

Authors:  Mark A Atkinson; Matthias von Herrath; Alvin C Powers; Michael Clare-Salzler
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

2.  Decoupling the Functional Pleiotropy of Stem Cell Factor by Tuning c-Kit Signaling.

Authors:  Chia Chi M Ho; Akanksha Chhabra; Philipp Starkl; Peter-John Schnorr; Stephan Wilmes; Ignacio Moraga; Hye-Sook Kwon; Nicolas Gaudenzio; Riccardo Sibilano; Tom S Wehrman; Milica Gakovic; Jonathan T Sockolosky; Matthew R Tiffany; Aaron M Ring; Jacob Piehler; Irving L Weissman; Stephen J Galli; Judith A Shizuru; K Christopher Garcia
Journal:  Cell       Date:  2017-03-09       Impact factor: 41.582

3.  Alpha cells, the main source of IL-1β in human pancreas.

Authors:  Florence Anquetil; Somayeh Sabouri; Charles Thivolet; Teresa Rodriguez-Calvo; Jose Zapardiel-Gonzalo; Natalie Amirian; Darius Schneider; Ericka Castillo; Yasaman Lajevardi; Matthias G von Herrath
Journal:  J Autoimmun       Date:  2017-03-18       Impact factor: 7.094

4.  CCL20 is elevated during obesity and differentially regulated by NF-κB subunits in pancreatic β-cells.

Authors:  Susan J Burke; Michael D Karlstad; Kellie M Regal; Tim E Sparer; Danhong Lu; Carrie M Elks; Ryan W Grant; Jacqueline M Stephens; David H Burk; J Jason Collier
Journal:  Biochim Biophys Acta       Date:  2015-04-13

5.  Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation.

Authors:  Fulya Erendor; Elif Ozgecan Sahin; Ahter D Sanlioglu; Mustafa Kemal Balci; Thomas S Griffith; Salih Sanlioglu
Journal:  Gene Ther       Date:  2020-07-30       Impact factor: 5.250

Review 6.  Influence of host immunoregulatory genes, ER stress and gut microbiota on the shared pathogenesis of inflammatory bowel disease and Type 1 diabetes.

Authors:  Altin Gjymishka; Roxana M Coman; Todd M Brusko; Sarah C Glover
Journal:  Immunotherapy       Date:  2013-12       Impact factor: 4.196

Review 7.  Interleukin-7 and type 1 diabetes.

Authors:  Paolo Monti; Ezio Bonifacio
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

Review 8.  Immune interventions to preserve β cell function in type 1 diabetes.

Authors:  Mario R Ehlers
Journal:  J Investig Med       Date:  2016-01       Impact factor: 2.895

Review 9.  Strategies for clinical trials in type 1 diabetes.

Authors:  Mario R Ehlers
Journal:  J Autoimmun       Date:  2016-04-05       Impact factor: 7.094

Review 10.  Neutralization Versus Reinforcement of Proinflammatory Cytokines to Arrest Autoimmunity in Type 1 Diabetes.

Authors:  Ayelet Kaminitz; Shifra Ash; Nadir Askenasy
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.